QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)

DELISTING OF QT VASCULAR LTD AND LISTING OF QUANTUM HEALTHCARE LIMITED

---

1. INTRODUCTION

The Board of Directors ("**Board**") of QT Vascular Ltd ("**Company**") refers to its announcements on 2 March 2022, 22 March 2022, 11 May 2022, 19 May 2022, 1 June 2022, 24 June 2022, 29 June 2022, 5 July 2022, 14 July 2022 and 20 July 2022 in relation to the Scheme and the Scheme Document dated 1 June 2022 (**"Scheme Document"**).

Unless otherwise defined, all capitalised terms used herein shall have the same meanings ascribed in the Scheme Document.

2. DELISTING OF THE COMPANY AND LISTING OF QUANTUM HEALTHCARE LIMITED

Pursuant to the Scheme, following the Proposed Restructuring and the Transfer of Listing Status, the Quantum Healthcare Shares will be listed and traded on the Catalist, and the Company will be delisted from Catalist with effect from 29 July 2022. Quantum Healthcare Shares is expected to be listed and quoted on the Catalist of the SGX-ST by 29 July 2022 and trading of the Quantum Healthcare Shares is expected to commence with effect from 9.00 a.m. on 29 July 2022.

The Board also wishes to announce that 6,893,072,507 new ordinary shares in the capital of Quantum Healthcare Limited (**"Quantum Healthcare"**) have been allotted and issued by Quantum Healthcare. The Quantum Healthcare Shares will be credited into the Securities Accounts of Depositors pursuant to the Scheme on 28 July 2022, on the basis of one (1) Quantum Healthcare Share for every one (1) Share held by each Entitled Shareholder as at the Record Date. Including the one (1) existing Quantum Healthcare Share, the total issued share capital of Quantum Healthcare following the allotment and issuance comprises 6,893,072,508 Quantum Healthcare Shares.

The Quantum Healthcare Shares shall be duly authorised, validly issued, credited as fully paid, free from Encumbrances, together with all rights, benefits and entitlements thereto, including the right to receive and retain (all dividends, rights and other distributions (if any) declared, paid or made by the Company on or after 2 March 2022, save for any dividends that may be paid by the Company prior to the Record Date, and shall rank *pari passu* in all respects with one another as well as the existing issued Quantum Healthcare Share.

3. UPDATES

The Company (or Quantum Healthcare, as the case may be) will continue to keep Shareholders updated as and when there are material developments in relation to the Scheme.

4. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm, after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Scheme as set out herein, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make

any statement in this announcement misleading.

Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

BY ORDER OF THE BOARD

Thomas Tan Gim Chua
Chief Executive Officer
27 July 2022

*This announcement has been reviewed by QT Vascular Ltd's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.